



Pharmaceutical Services, 2 Franklin Street, Belfast BT2 8DQ  
Telephone No. 028 95 36 0333

**UPDATE:** Updates to communication (MPS 3386) issued 16 June 2025 in **bold**

### Medicine Supply Notification:

Levemir® (insulin detemir) FlexPen® 100units/ml solution for injection 3ml pre-filled pens and  
Levemir® (insulin detemir) Penfill 100units/ml solution for injection 3ml cartridges  
Tier 2 – medium impact  
Date of issue: 14/08/2025

[Medicines Supply Tool – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice](#)

### Summary

- Levemir® (insulin detemir) FlexPen® 100units/ml solution for injection 3ml pre-filled pens and Levemir® (insulin detemir) Penfill® 100units/ml solution for injection 3ml cartridges are being discontinued; stock is anticipated to be exhausted by the end of 2026.
- **[Clinical guidance](#) has been produced by clinical experts (see Supporting information).**
- **Current supply positions and ability of alternative insulins to support an increase in demand is summarised below. Any changes to availability will be communicated via the [SPS Medicines Supply Tool](#).**

## Actions Required

Clinicians should:

- not initiate new patients on any Levemir® product; and
- **begin implementing insulin switches for all existing Levemir® patients in line with the [clinical guidance](#) (see Supporting information).**

**Local teams should avoid initiating widespread switches without checking the current supply overview of alternative insulins to reduce the risk of precipitating a supply disruption of these products (see Supporting information).**

**As recommended in the [clinical guidance](#), clinicians should aim to diversify prescribing across available alternatives to reduce supply risk where possible.**

**In addition to consulting the [clinical guidance](#), when prescribing alternatives, consider manual dexterity, vision, and whether additional support is required for administration, and:**

- **ensure that all patients/carers are counselled on dose to be administered, provided with training on the use of their new device, as well as appropriate ancillaries, including signposting to training videos; and**
- **advise patients that closer monitoring of blood glucose levels is required initially, and their insulin dose may need to be adjusted.**

**Seek advice from specialist diabetes teams where required.**

OFFICIAL-SENSITIVE

## Supporting information

### Supply summary table

Levemir is a long-acting insulin analogue **with a prolonged duration of effect** used as a basal insulin. It is licensed for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. It can be used alone as the basal insulin or in combination with bolus insulin. **It can also be used in combination with oral antidiabetic medicinal products and/or GLP-1 receptor agonists.**

**As insulin glargine is available in two strengths, these products must be prescribed BY BRAND to minimise the risk of product mis-selection.**

Insulin type		Supply overview	
Insulin type	Brand name and devices	Stock status	Ability to support increased demand
Insulin glargine U100 (Long acting)	Abasaglar® KwikPen®	In stock	Cannot support
	Abasaglar® cartridges	In stock	Cannot support
	Lantus® SoloStar®	In stock	Can support
	Lantus® cartridges	In stock	Can support
	Semglee® pre-filled pens (biosimilar)	In stock	Can support
Insulin glargine U300 (Ultralong acting)	Toujeo® SoloStar®	In stock	Can support
	Toujeo® DoubleStar®	In stock	Can support
Insulin degludec (Ultralong acting)	Tresiba® U100 FlexTouch®	Out of stock until early January 2026	Cannot support
	Tresiba® U100 cartridges	In stock	Can support
	Tresiba® U200 FlexTouch®	In stock	Can support
Human isophane insulin (intermediate acting)	Humulin I® KwikPen®	In stock	Cannot support
	Humulin I® cartridges	In stock	Cannot support

### Links to further information

[Clinical Guideline: Discontinuation of Levemir®](#)

[BNF Insulin detemir](#)

[BNF Insulin preparations](#)

[NICE guidance: Type 1 diabetes in adults \(insulin therapy\)](#)

[NICE CKS- Insulin therapy in type 1 diabetes](#)

[NICE CKS- Insulin therapy in type 2 diabetes](#)

[SmPC Levemir®](#)

[SmPC Lantus®](#)

[SmPC Toujeo®](#)

[SmPC Abasaglar®](#)

[SmPC Semglee®](#)

[SmPC Tresiba®](#)

[SmPC Humulin® I](#)

[SPS Medicines Supply Tool - Shortage of Tresiba \(insulin degludec\) FlexTouch 100units/ml solution for injection 3ml pre-filled pens](#)